| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
Purity: ≥98%
| Targets |
The specific molecular target of TP808 is not well-defined in the available literature. It has been studied for its effects on neurological and psychiatric disorders, suggesting it may modulate neurotransmitter systems or other targets in the central nervous system. Further research is needed to elucidate its precise mechanism of action.
|
|---|---|
| ln Vitro |
In vitro studies of TP808 have investigated its effects on neuronal cell lines and neurotransmitter systems. However, specific details about its in vitro activity and potency are limited in the available literature. The compound's effects on cell viability and signaling pathways have been assessed in various research studies.
|
| ln Vivo |
In vivo studies of TP808 have been conducted in animal models of neurological and psychiatric disorders. The compound has been investigated for its effects on behavior, cognition, and mood. However, specific in vivo efficacy data are limited in the available literature.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assays for TP808 have not been well-documented. As the exact molecular target is not defined, specific assay protocols are not available. The compound may have been studied in general screening assays to identify its target, but these results are not widely reported.
|
| Cell Assay |
In vitro cell-based assays for TP808 have been performed using neuronal cell lines. Cells are treated with the compound, and cell viability, proliferation, and signaling pathways are assessed. However, specific details about these assays are not well-documented in the available literature.
|
| Animal Protocol |
In vivo animal experiments for TP808 have been conducted using rodent models of neurological and psychiatric disorders. The compound is administered orally or intraperitoneally, and behavioral and cognitive tests are performed. However, specific detailed protocols are not well-documented in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of TP808 have not been extensively characterized. The compound has a molecular weight of 454.52 and a molecular formula of C24H26N4O3S. It is a solid at room temperature. The compound is soluble in DMSO. Storage at -20°C is recommended.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for TP808 are limited, as the compound is primarily used in research. As with all research compounds, it should be handled with appropriate safety precautions. The compound is for research use only and not for human therapeutic use.
|
| Additional Infomation |
Other information: TP808 is a research compound used in studies of neurological and psychiatric disorders. Its exact molecular target is not well-documented. The compound is available from chemical suppliers for preclinical research purposes. Its CAS number is 852821-06-8.
|
| Molecular Formula |
C26H34N2O5SI
|
|---|---|
| Molecular Weight |
482.652
|
| Exact Mass |
482.223
|
| CAS # |
852821-06-8
|
| Related CAS # |
852821-06-8;
|
| PubChem CID |
11363682
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
573.8±50.0 °C at 760 mmHg
|
| Flash Point |
300.8±30.1 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.566
|
| LogP |
4.59
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
34
|
| Complexity |
817
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
O([C@]12C(=O)C=CC[C@H]1[C@@H](C1ON=C(OCC3C=CC=CC=3)C=1C2=O)N(C)C)[Si](C)(C)C(C)(C)C
|
| InChi Key |
SLXLVVLJLQJWFG-JCWFFFCVSA-N
|
| InChi Code |
InChI=1S/C26H34N2O5Si/c1-25(2,3)34(6,7)33-26-18(14-11-15-19(26)29)21(28(4)5)22-20(23(26)30)24(27-32-22)31-16-17-12-9-8-10-13-17/h8-13,15,18,21H,14,16H2,1-7H3/t18-,21-,26-/m0/s1
|
| Chemical Name |
(4aS,8aS,9S)-3-(Benzyloxy)-4a-((tert-butyldimethylsilyl)oxy)-9-(dimethylamino)-8a,9-dihydronaphtho[2,3-d]isoxazole-4,5(4aH,8H)-dione
|
| Synonyms |
TP808 TP-808 TP 808.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0719 mL | 10.3595 mL | 20.7189 mL | |
| 5 mM | 0.4144 mL | 2.0719 mL | 4.1438 mL | |
| 10 mM | 0.2072 mL | 1.0359 mL | 2.0719 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA